



clonoSEQ®

Measure cancer

like you face it.

clonoSEQ® is a measurable (or minimal) residual disease (MRD) test that can detect the number of cancer cells that may remain in your body during and after therapy, so you and your doctor can make more informed treatment decisions.¹

FDA-cleared for multiple myeloma, ALL, and CLL
CLIA-validated for DLBCL, MCL, and other lymphoid cancers.

Cancer detection that's as powerful as you are


Treatment for blood cancer has come a long way. To make the most of today's therapies, your doctor needs advanced tools to measure your response, so you can both feel confident in your treatment plan.²⁻⁴

clonoSEQ

(pronounced clo-no-seeq) is a test that detects and tracks changes in **measurable residual disease (MRD)** over time, so you and your doctor can make informed, personalized decisions throughout your treatment.¹

What is MRD?

MRD refers to the number of cancer cells that can stay in the body during and after treatment. These cells can be present at very low levels, which may be a sign your cancer is returning.¹ Keeping an eye on MRD is important because it can help you and your doctor decide what to do next.²⁻⁴



clonoSEQ is a test that keeps up with today's cancer treatments

clonoSEQ is a blood or bone marrow test that gives you and your doctor a personalized way to assess your body's individual response to treatment.¹


clonoSEQ can:

- ✓ Detect very small amounts of cancer that other tests may miss⁵⁻⁷
- ✓ Help you understand where you are in your cancer journey^{2-4,8}
- ✓ Help your doctor tailor treatment to your needs^{2-4,8}

Measure, then treat. Treat, then measure.

Repeat throughout your journey

Your MRD levels may change over time. The curve below shows how clonoSEQ helps you and your doctor follow, understand, and react to these changes.²⁻⁴



Managing cancer takes courage and consistency.

"If there was one word to describe receiving my MRD results, I would say, hope."

- Tiffany, a multiple myeloma patient who had clonoSEQ testing

clonoSEQ is covered by Medicare and other major insurance providers for myeloma, DLBCL, CLL, and B-ALL.



Adaptive
assist™

Patient Support Program

We can help you:

- Understand coverage and potential out-of-pocket costs
- Navigate insurance and billing
- Appeal all denials on your behalf

90% of patients pay
\$0 for clonoSEQ*

Learn more at
adaptive-assist.com

Need help with Adaptive Assist?
Call 1-855-236-9230

*Based on insurance coverage and prior to applying any Adaptive-provided financial assistance.

Talk to your doctor
about clonoSEQ testing



Here are some questions to get the conversation started:

- How might clonoSEQ MRD results inform my treatment plan?
- At what points during or after treatment should we use clonoSEQ MRD testing?
- When might blood-based clonoSEQ MRD testing be right for me?

Find a provider who tests
for MRD with clonoSEQ

clonoSEQ® is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). Additionally, clonoSEQ is available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

References:

1. clonoSEQ®. [technical summary]. Seattle, WA. Adaptive Biotechnologies; 2020.
2. Martinez-Lopez J, et al. *J Hematol Oncol*. 2021;14(1):126.
3. Friend BD, et al. *Pediatr Blood Cancer*. 2020;67(2):e28079.
4. Al-Sawaf O, et al. *J Clin Oncol*. 2021;39(36):4049-4060.
5. Avet-Loiseau H, et al. *Blood*. 2015;126(23):191.
6. Short NJ, et al. *Blood Adv*. 2022;6(13):4006-4014.
7. Wood B, et al. *Blood*. 2018;131(12):1350-1359.
8. Costa LJ, et al. *Lancet*. 2023;10.1016/S2352-3026(23)00236-3.

©2024 Adaptive Biotechnologies Corp. All rights reserved.

clonoSEQ®